American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

Published on by David Neskey

David Neskey – Charleston, South Carolina

Practice Contact Information

Medical University of South Carolina
135 Rutledge Avenue
MSC 550
Charleston
South Carolina
29403
United States

Phone:
Email: [email protected]
Web Site:

Areas of surgical specialization in Head and Neck Surgery

Head and Neck Research, Head and Neck Surgeon

Biography/Statement

David M. Neskey, M.D., MSCR, FACS is an assistant professor in the Department of Otolaryngology in the division of Head and Neck Surgical Oncology.  Originally from Massachusetts he received his medical degree from Albany Medical College with a distinction in research in 2006 followed by a residency in Otolaryngology Head and Neck Surgery at the University of Miami.  He then completed a fellowship in head and neck surgical oncology at MD Anderson Cancer Center in Houston.  This training experience was comprised of two years dedicated to basic science research followed by a year committed to the management of patients with head and neck cancer.

Dr Neskey’s clinical focus is on the care of patients with benign and malignant neoplasias of the head and neck including oral cavity, oropharyngeal, laryngeal lesions, and skullbase,  advanced melanoma and nonmelanoma skin cancers, and lesions of the salivary glands, thyroid and parathyroids.  His specific interests are squamous cell carcinoma of the oral cavity and oropharynx along with advanced skin cancer and skull base tumors.  He currently sees patients in Hollings Cancer Center.

Dr Neskey has published over 30 peer reviewed articles and book chapters  focused on the molecular pathways and genomic alterations associated with head and neck squamous cell carcinoma.  Based on this work he is currently funded through the National Institute of Health to study the mechanisms of invasion and metastases in head and neck cancer.  In addition to his lab based studies, Dr. Neskey is the principle investigator in several ongoing trials, including an investigator initiated trial investigating immunotherapy a presurgical treatment for patients with oral cavity cancer. He is board certified by the American Board of Otolaryngology and is a member of the American Head and Neck Society, American Academy of Clinical Research, and a Fellow of the American College of Surgeons.

Clinical Trials

Investigator Initiated Phase II Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer (NCT03021993).

Role: Sponsor and PI

Bibliography

  1. Fabie JE, Hatch JL, Cross AW, Oyer AW, Neskey DM, McRackan TR. Metastatic Salivary Ductal Carcinoma to the Mastoid Segment of the Facial Nerve. Otol Neurotol. 2018 Jul 30. doi: 10.1097/MAO.0000000000001923. [Epub ahead of print] PMID:30063500
  2. Janz TA, Neskey DM, Nguyen SA, Lentsch EJ. Is imaging of the brain necessary at diagnosis for cutaneous head and neck melanomas? Am J Otolaryngol. 2018 Jun 8. pii: S0196-0709(18)30415-0. doi: 10.1016/j.amjoto.2018.06.007. [Epub ahead of print] Review.
  3. Grauzam S, Brock AM, Holmes CO, Tiedeken JA, Boniface SG, Pierson BN, Patterson DG, Coaxum SD, Neskey DM, Rosenzweig SA. NEDD9 stimulated MMP9 secretion is required for invadopodia formation in oral squamous cell carcinoma. Oncotarget. 2018 May 22;9(39):25503-25516. doi: 10.18632/oncotarget.25347. eCollection 2018 May 22.
  4. Zhan KY, Morgan PF, Neskey DM, Kim JJ, Huang AT, Garrett-Mayer E, Day TA. Preoperative predictors of occult nodal disease in cT1N0 oral cavity squamous cell carcinoma: Review of 2623 cases. Head Neck. 2018 May 14. doi: 10.1002/hed.25178. [Epub ahead of print]
  5. Ellis MA, Graboyes EM, Wahlquist AE, Neskey DM, Kaczmar JM, Schopper HK, Sharma AK, Morgan PF, Nguyen SA, Day TA.  Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. Otolaryngol Head Neck Surg. 2017 Dec 1:194599817746909. doi: 10.1177/0194599817746909. PMID: 29256326
  6. Borucki RB, Neskey DM, Lentsch EJ. Malignant Fibrous Histiocytoma: Database Review Suggests a Favorable Prognosis in the Head and Neck. Laryngoscope. 2017 Oct 8. doi10.1002/lary.26909. PMID: 28988458
  7. Ellis MA, Graboyes EM, Day TA, Neskey DM. Prognostic Factors and Occult Nodal Disease in Carcinoma of the Oral Cavity and Oropharynx: An Analysis of the National Mucoepidermoid Cancer Database.  Oral Oncol. 2017 Sep; 72:174-178. doi:10.1016/j.oraloncology.2017.07.025. Epub 2017 Jul 27.  PMID: 28797455
  8. Coaxum SD, Tiedeken J, Garrett-Mayer E, Myers JN, Rosenzweig SA, Neskey DM. The Tumor Suppressor Capability of p53 is Dependent on Non-Muscle Myosin IIA in Head and Neck Cancer. Oncotarget. 2017 Jan. doi:10.18632/oncotarget.14967. PMID: 28160562
  9. Ellis MA, Gerry DR, Neskey DM, Lentsch EJ.  Ewing Sarcoma of the Head and Neck. Ann Otol Rhinol Laryngol. 2017 Mar; 126(3):179-184. doi: 10.1177/0003489416681322. PMID: 28056517
  10. Majumder M, House R, Palanisamy N, Qie S, Day TA, Neskey DM, Diehl JA, Palanisamy V. RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC. PLoS Genet. 2016 Sep 8; 12(9):e1006306. doi: 10.1371/journal.pgen.1006306. PMID: 27606879
  11. *Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Ortega Alves M, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN.  Evolutionary Action Score of TP53 Coding Variants (EAp53) is Predictive of Platinum Response in Head and Neck Cancer Patients.  Cancer Res. 2015 Feb 17. pii: canres.2729.2014. * Denotes shared first author
  12. Neskey DM, Osman AO, Ow TJ, Dr., Katsonis P , McDonald T, Hicks SC, Hsu TK, Pickering CR, Ms. Ward A, Patel A, Yordy JS, Skinner HD, Giri U, Sano D, Story MD, Beadle BM, El-Naggar AK, Kies MS, William WN, Caulin C, Frederick M, Kimmel M, Myers, JN, Lichtarge O.  Evolutionary Action Score of TP53 (EAp53) Identifies High Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Research 2015 Jan 29. pii: canres.2735.2014.
  13. Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN.  Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence.  Mol Cancer Ther. 2014 Dec 10. pii: molcanther.0735.2014.
  14. Pickering CR, Zhang J, Neskey DM, Zhao M, Jasser SA, Wang J, Ward A, Tsai CJ, Ortega Alves MV, Zhou JH, Drummond JA, El-Naggar AK, Gibbs RA, Weinstein JN, Wheeler DA, Wang J, Frederick MJ, Myers JN.  Squamous Cell Carcinoma of the Oral Tongue in Young Non-smokers is Genomically Similar to Tumors in Older Smokers.  Clin Cancer Res. 2014 May 29. pii: clincanres.0565.2014. [Epub ahead of print].
  15. Neskey DM, Klein JD, Hicks S, Garden AS, Bell D, El-Naggar AK, Kies MS, Weber RS, Kupferman ME.  Prognostic Factors Associated Decreased Survival in Acinic Cell Carcinoma.  JAMA Otolaryngol Head Neck Surg. 2013 Sep 26. doi: 10.1001/jamaoto.2013.4728
  16. Gadhikar MA, Sciuto MR, Ortega Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ.  Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.  Mol Cancer Ther. Mol Cancer Ther. 2013 Sep;12(9):1860-73.
  17. Yang CZ, Ma J, Luo QQ, Neskey DM, Zhu DW, Liu Y, Myers JN, Zhang CP, Zhang ZY, Zhong LP.  Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.  J Oral Pathol Med. 2013 May 26. doi: 10.1111/jop.12091. [Epub ahead of print].
  18. Pickering CR, Zhang J Suk, Yoo SY, Neskey DM, Xie TX, El-Naggar AK, Weinstein JN, Wang J, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ.  Integrated genomic characterization of oral cavity squamous cell carcinoma identifies frequent genomic drivers.  Cancer Discovery.  2013 Apr 25. [Epub ahead of print].
  19. Perez A, Neskey DM, Wen J, Pereira L, Reategui EP, Goodwin WJ, Carraway KL, Franzmann EJ.  CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression.  Oral Oncol. 2013 Apr;49(4):306-13.  Epub 2012 Dec 20.
  20. Eloy JA, Neskey DM, Vivero RJ, Ruiz JW, Choudhry OJ, Casiano RR.  High-resolution computed tomography analysis of the frontal sinus ostium: A pilot study.  Am J Otolaryngol. 2013 Mar; 34(2):99-102. Epub 2012 Oct 23.
  21. Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, Zhong LP.  Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: A meta-analysis.  Oral Oncol. 2012 Jul 14. Epub ahead of print
  22. Neskey DM, Hatoum G, Modh R, Civantos F, Telischi FF, Angeli S, Weed D, Sargi Z.  Outcomes after surgical resection of head and neck paragangliomas: A review of 61 patients.  Skull Base.  21:171-76, 2011
  23. Neskey DM, Eloy JA, Casiano RR.  Nasal, septal, and turbinate anatomy and embryology.  Otolaryngology Clinics of North America.  42;193-205, 2009.
  24. Lee SL, Neskey DM, Mouzakes J.  Potential predisposition for nasal septal perforation with methotrexate use: report of 2 cases and literature review.  Ear Nose Throat J.  88(8):12-4, 2009.
  25. Neskey DM, Ambesi AA, Pumiglia KM, McKeown-Longo PJ.  Endostatin and anastellin inhibit distinct aspects of the angiogenic process.  J Exp Clin Cancer Res. 27:61-68, 2008 November.
  26. Gross KL, Neskey DM, Manchanda N, Weremowicz S, Kleinman MS, Nowak RA, Ligon AH, Rogalla P, Drechsler K, Bullerdiek J, Morton CC.  HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies.  Genes, Chromosomes, & Cancer.  38(1):68-79, 2003 September.
  27. Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, Morton CC.  Fusion transcripts involving HMGA2 are not a common molecular mechanism on uterine leiomyomata with rearrangements in 12q15.  Cancer Research.  63(6):1351-8, 2003 March.
  28. Dal Cin P, Quade BJ, Neskey DM, Kleinman MS, Weremowicz S, Morton CC.  Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24).  Genes, Chromosomes, & Cancer.  36(2):05-6, 2003 February.
  29. Quade BJ, Dal Cin P, Neskey DM, Weremowicz S, Morton CC.  Intravenous Leiomyomatosis: molecular and cytogenetic analysis of a case.  Modern Pathology.  15(3):351-6, 2002 March.
  30. Nucci MR, Weremocicz S, Neskey DM, Sornberger K, Tallini G, Morton CC, Quade BJ.  Chromosomal Translocation t(8;12) Induces Aberrant HMGIC Expression in Aggressive Angiomyxomas of the Vulva.  Genes, Chromosomes, and Cancer.  32(2):172 -176, 2001 October.

Published on by Ashley Mays, MD

Ashley Mays – Baton Rouge, LA

Practice Contact Information

Louisiana State University (LSU) Health Sciences Department of Otolaryngology
4950 ESSEN LANE, SUITE 400

Baton Rouge
LA
70809
United States

Phone:
Email:
Web Site:

Areas of surgical specialization in Head and Neck Surgery

Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon, Reconstructive Head & Neck Surgery

Biography/Statement

A native of Taylorsville, North Carolina, Dr Mays received her medical education at the Brody School of Medicine at East Carolina University in Greenville, North Carolina and completed her otolaryngology residency at Wake Forest University, in Winston-Salem, North Carolina. She completed a two-year fellowship in Head and Neck Surgical Oncology and Total Body Microvascular Reconstruction at UT MD Anderson Cancer Center, in Houston, Texas.

 

Throughout her training, Dr Mays has made research contributions to head and neck oncology in both the clinical and translational realms. She has been recognized regionally by her peers for her role in cancer patient advocacy, through numerous volunteer and leadership roles. She is looking forward to furthering her research and cancer advocacies efforts in the Baton Rouge, Louisiana area.

 

Dr Mays will be seeing patients with head and neck cancer, upper aerodigestive tract lesions, and complex reconstructive deficits. She has interests in robotic surgery of the head and neck (TORS), endoscopic skull base surgery, and total body microvascular reconstructive surgery.

Clinical Trials

Bibliography

Published on by Antoine Melkane

Antoine Melkane – Ashrafieh, Beirut

Practice Contact Information

Saint Joseph University, Hotel Dieu de France Hospital
Alfred Naccache Blvd

Ashrafieh
Beirut
166830
Lebanon

Phone: 00961 1 604000, ext. 9612
Email: [email protected]
Web Site:

Areas of surgical specialization in Head and Neck Surgery

Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon, Reconstructive Head & Neck Surgery

Biography/Statement

Dr. Antoine Melkane is currently an Assistant Professor in the Department of Otolaryngology at the Saint Joseph University School of Medicine.

Dr. Melkane graduated from the Saint Joseph University School of Medicine, Beirut, Lebanon in 2004. After completing his residency in Otolaryngology – Head and Neck Surgery at the Hotel Dieu de France University Hospital, Beirut, Lebanon (2004-2009), he underwent fellowship training in Head and Neck Cancer Surgery at the Gustave Roussy Institute, Paris XI University, Villejuif, France (2009-2012), then at the Karmanos Cancer Institute, Wayne State University, MI, USA (2012-2013).

Dr. Melkane joined the faculty at the Hotel Dieu de France University Hospital in 2014 and is actively involved in the care of patients with head and neck cancers, developing both oncologic and reconstructive surgeries.

Dr. Melkane holds a Master of Surgical Science from the Paris XI University, Paris, France (2012). His main research interests involve the implication of Human Papillomavirus in oropharyngeal cancers, the role of sentinel node biopsy in early oral cancers, and the application of confocal laser endomicroscopy in head and neck cancers.

Clinical Trials

Bibliography

Mhawej R, Ghorra C, Naderi S, Khoueir N, Abou Hamad W, Melkane AE. Human papillomavirus prevalence and clinicopathological associations in oropharyngeal squamous cell carcinoma in the Lebanese population. J Laryngol Otol. 2018 Jun 29: 1-6.

Moya-Plana A, Aupérin A, Guerlain J, Gorphe P, Casiraghi O, Mamelle G, Melkane A, Lumbroso J, Janot F, Temam S. Sentinel node biopsy in early oral squamous cell carcinomas: Long-term follow-up and nodal failure analysis. Oral Oncol. 2018 Jul; 82: 187-194.

Mirghani H, Casiraghi O, Guerlain J, Amen F, He MX, Ma XJ, Luo Y, Mourareau C, Drusch F, Lakdhar AB, Melkane A, St Guily L, Badoual C, Scoazec JY, Borget I, Aupérin A, Dalstein V, Vielh P. Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test. Oral Oncol. 2016 Nov; 62: 101-108.

Cohen DS, Low GM, Melkane AE, Mutchnick SA, Waxman JA, Patel S, Shkoukani MA, Lin HS. Establishing a danger zone: An anatomic study of the lingual artery in base of tongue surgery. Laryngoscope. 2017 Jan; 127(1): 110-115.

Mhawej R, Richa T, Melkane AE. Benign lymphoepithelial cyst of unusual location: a case report. Acta Oto-Laryngologica Case Reports. 2016 Nov; 1(1): 110-112.

Hurst NJ, Dominello M, Dyson G, Jaratli H, Sharma M, Ahmed Y, Melkane AE, Rose CT, Jacobs JR, Giorgadze T, Kim H. Intratumoral lymphatic vessel density as a predictor of progression-free and overall survival in locally advanced laryngeal/hypopharyngeal cancer. Head Neck. 2016 Apr; 38 Suppl 1: E417-20.

Lacroix L, Post S, Valent A, Melkane AE, Lefebvre AM, Egile C, Castell C, Saulnier P, Goulaouic H, Temam S. MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma. PLoS One. 2014 Jan 17; 9(1): e84319.

Mirghani H, Amen F, Moreau F, Guigay J, Ferchiou M, Melkane AE, Hartl DM, Lacau St Guily J. Human papilloma virus testing in oropharyngeal squamous cell carcinoma: what the clinician should know. Oral Oncol. 2014 Jan; 50(1): 1-9.

Melkane AE, Mirghani H, Auperin A, Saulnier P, Lacroix L, Vielh P, Casiraghi O, Griscelli F, Temam S. HPV-related oropharyngeal squamous cell carcinomas: a comparison between three diagnostic approaches. Am J Otolaryngol. 2014 Jan-Feb; 35(1): 25-32.

Melkane AE, Auperin A, Saulnier P, Lacroix L, Vielh P, Casiraghi O, Msakni I, Drusch F, Temam S. Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas. Head Neck. 2014 Feb; 36(2): 257-65.

Melkane AE, Mamelle G, Wycisk G, Temam S, Janot F, Casiraghi O, Lumbroso J. Sentinel node biopsy in early oral squamous cell carcinomas: a ten-year experience. Laryngoscope. 2012 Aug; 122(8): 1782-8. 

Aouad R, Matar N, Melkane A, Nassar M, Almoutran H, Haddad A. Sulfuric acid ingestion. J Trauma. 2011 May; 70(5): E98. 

Melkane AE, Matar N, Haddad A, Zoghbi A. Suicidal hanging attempt: poor symptoms for a potentially lethal injury. J Trauma. 2010 Oct; 69(4): E36. 

Aouad R, Melkane A, Rassi S. Lemierre’s syndrome: unusual cause and presentation. Pediatr Emerg Care. 2010 May; 26(5): 376-7. 

Melkane AE, Matar NE, Haddad AC, Nassar MN, Almoutran HG, Rohayem Z, Daher M, Chalouhy G, Dabar G. Management of post-intubation tracheal stenosis: appropriate indications make outcome differences. Respiration. 2010; 79(5): 395-401.

Abboud B, Sleilaty G, Braidy C, Melkane A, Nasr F. Thyroidectomy in patients at high-risk of bleeding: can it be safely performed? Minerva Chir. 2009 Dec; 64(6): 565-71.

Rassi SJ, Melkane AE, Rizk HG, Dahoui HA. Sinonasal mucormycosis in immunocompromised pediatric patients. J Pediatr Hematol Oncol. 2009 Dec;31(12): 907-10.

Matar NE, Rassi SJ, Melkane AE, Haddad AC. Lateral sinus thrombosis in the pediatric population: multiple presentations for a potentially lethal disease. Pediatr Emerg Care. 2009 Oct; 25(10): 681-3.

Razfar A, Walvekar R, Melkane A, Johnson J, Myers E. Incidence and patterns of regional metastasis in early oral squamous cell cancers: feasibility of submandibular gland preservation. Head Neck. 2009 Dec; 31(12): 1619-23.

Published on by R. Bryan Bell

R. Bryan Bell – Portland, OR

Practice Contact Information

Providence Cancer Institute
4805 NE Glisan St. Suite 2N35

Portland
OR
97213
United States

Phone: 503-215-3053
Email: [email protected]
Web Site: https://oregon.providence.org/our-services/p/providence-oral-head-and-neck-cancer-program/

Areas of surgical specialization in Head and Neck Surgery

Head and Neck Research, Head and Neck Surgeon, Reconstructive Head & Neck Surgery

Biography/Statement

Dr. Bell is a fellowship-trained Head and Neck Oncologic Surgeon/Maxillofacial Surgeon whose clinical practice, teaching and research is devoted to the comprehensive surgical management of patients with head and neck cancer. Dr. Bell is currently Director of the Providence Head and Neck Cancer Program and Clinic at the Providence Cancer Institute, where he also directs a Fellowship in Head and Neck Oncologic and Microvascular Reconstructive Surgery, and is an Associate Member of the Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center. He has served in leadership positions with numerous professional societies, boards, foundations and committees and is Past President of the American Academy of Craniomaxillofacial Surgeons and the American College of Oral and Maxillofacial Surgeons.

Dr. Bell has pioneered the use of virtual surgical planning in head and neck surgery and was one of the first surgeons on the U.S. west coast to perform transoral robotic surgery for oropharyngeal and laryngeal cancer. Since joining the Earle A. Chiles Research Institute, Dr. Bell has fostered an institutional commitment to head and neck cancer immunotherapy research through numerous scientific collaborations.   Using his surgical practice to run phase I and phase II trials studying reversal of immunosuppression through monoclonal antibody therapy to enhance surgical resection, Dr. Bell bridges basic, translational and clinical activities. His work has resulted in over 150 scientific articles and book chapters, and he is co-editor of two major textbooks, including Oral, Head and Neck Oncology and Reconstructive Surgery. In addition, he has given more than 250 invited lectures, highlighting his interests in virtual surgical planning, transoral robotic surgery and immunotherapy for head and neck cancer.

 

Clinical Trials

 

Bibliography

https://www.ncbi.nlm.nih.gov/sites/myncbi/1vsCreBjecO5y/bibliography/46721857/public/?sort=date&direction=descending

 

Published on by Mark Swanson

Mark Swanson – Los Angeles, California

Practice Contact Information

University of Southern California – Keck Medical Center
1450 San Pablo Street

Los Angeles
California
90033
United States

Phone: 323-442-5790
Email:
Web Site: https://keck.usc.edu/otolaryngology/faculty/Mark-Swanson/

Areas of surgical specialization in Head and Neck Surgery

Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon, Reconstructive Head & Neck Surgery

Biography/Statement

Mark Swanson, MD is a fellowship trained head and neck surgeon. After completing medical school at the Ohio State University, he entered a residency in Otolaryngology at University of Southern California. He continued his training with a fellowship in cancer and reconstructive surgery at the University of Miami, and returned to USC to join the faculty at Keck Medical Center. His expertise is in treatment of benign and malignant tumors of the mouth, throat, salivary glands, neck, and thyroid gland. He utilizes advanced robotic, organ preservation, and microvascular reconstructive techniques to maximize quality of life after treatment.

Dr. Swanson works in a multi-disciplinary team including surgeons, radiation oncologists, medical oncologists, and speech/swallow therapists to provide complete care for head and neck diseases.

In addition to treating patients, Dr. Swanson has a research interest in oncologic and quality of life outcomes in head and neck cancers. He focuses on swallowing and voice outcomes after cancer treatments, and is working to provide optimal cancer outcomes while preserving unaffected tissues.

Clinical Trials

Head and neck squamous cell cancer related trials

Bibliography

Bertelsen C, Swanson MS, et al. Contrast-Enhanced Ultrasound with Perflubutane for Sentinel Lymph Node Mapping in Cutaneous Melanoma: A Pilot Study. Laryngoscope – In Press

 Swanson MS, Low G, Sinha UK, Kokot N. Transoral surgery vs intensity-modulated radiotherapy for early supraglottic cancer: a systematic review. Current opinion in otolaryngology & head and neck surgery. April 2017, 25 (2):133-141. [PMID 28106658]

 Swanson MS, Kokot N, Sinha UK. The Role of HPV in Head and Neck Cancer Stem Cell Formation and Tumorigenesis. Cancers. 2016; Feb 19;8(2): 24. [PMID 2907349]

Ouyoung, L.M., M.S. Swanson, B.C. Villegas, et al., ABCLOVE: Voice therapy outcomes for patients with head and neck cancer. Head Neck, 2016. 38 Suppl 1: p. E1810-3. [PMID 26689974]

Swanson MS, Hudson R, Bhandari N, Sinha UK, Maceri DR, Kokot N. Use of Octreotide for the Management of Chyle Fistula Following Neck Dissection. JAMA Otolaryngol Head Neck Surg. 2015 Aug;141(8):723-7. [PMID 26135979]

 Swanson MS, Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in Advanced Head and Neck Squamous Cell Cancer – Review of Current Data. Oral Oncology. 2015 Jan; 51(1):12-15. [PMID 25459157]

 Swanson MS, Brown, TN. Laryngotracheal giant cell tumor: case report and literature review. Case reports in Clinical Pathology. 2015; 2(2).  http://dx.doi.org/10.5430/crcp.v2n2p12 [DOI: 10.5430/crcp.v2n2p12]

 Swanson MS, Sinha UK. Diagnosis and Management of Merkel Cell Carcinoma of the Head and Neck: Current Trends and Controversies. Cancers. 2014; 6(3):1256-1266.  [PMID 24978433]

Radhakrishnan V, Swanson MS, Sinha UK. Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers. AIMS Medical Science, 2015, 2(4): 347-359. [DOI: 10.3934/medsci.2015.4.347]